1. Japan Stocks

  2. •

    Retail trade

  3. •

    Drugstore chains
SATUDORA HOLDINGS CO., LTD.

SATUDORA HOLDINGS CO., LTD.

TTSE:3544
1,248.00
JPY
0.00
(0.00%)
11.34BMarket Cap
Dec 18Next Earn
SATUDORA HOLDINGS CO., LTD.
TSE:3544
(Tokyo Stock Exchange)

Recent

price

1,248.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
- -
3,819.7
4,052.97
4,286.87
4,649.19
5,281.76
6,372.99
5,693.79
6,141.24
6,478.97
6,039.07
6,012.14
6,339.19
6,914.13
7,244.8
7,301.97
- -
Revenue per Share
- -
48.81
50
52.77
35.45
43.76
51.36
10.81
2.1
8.34
41.64
22.92
6.3
34.02
55.47
31.51
- -
Basic EPS, GAAP
- -
19.55
39.63
31.41
-142.51
-91.3
-53.9
-25.17
-99.61
-61.81
79.37
-54.39
-285.43
134.27
55.76
-24.76
- -
Free Cash Flow per Basic Share
- -
4.67
7.76
7.77
9.94
8.08
8.92
11.61
9.29
9.29
9.29
9.28
9.28
9.99
9.98
9.95
- -
Dividend per Share
313.53
357.67
400.04
445.18
469.05
562.83
607.23
606.37
599.98
596.07
625.89
637.7
632.36
659.28
711.81
733.29
- -
Book Value per Share
306.24
349.93
391.69
431.61
449.16
543.1
582.93
576.99
560.74
565.75
594.84
605.01
603.6
625.26
643.07
629.96
- -
Tangible Book Value per Share
- -
12
12
12
12
12
14
14
14
14
14
14
14
14
14
14
14
Basic Weighted Avg Shares
- -
44,171
46,869
49,574
53,763
62,767
87,844
78,482
84,649
89,304
83,240
82,905
87,481
95,520
100,174
100,571
- -
Sales/Revenue/Turnover
- -
2.48
2.5
2.05
1.31
1.66
1.5
0.98
0.51
0.92
0.77
0.9
0.34
1.45
1.67
1.45
- -
Operating Margin (%)
- -
544
604
628
759
879
1,205
1,053
1,254
1,213
1,164
1,203
1,279
1,327
1,387
1,535
- -
Depreciation Expense
- -
564
578
610
410
520
708
149
29
115
574
316
87
470
767
434
- -
Net Income, GAAP
- -
43.63
43.62
39.63
36.82
42.94
36.18
65.46
65.64
77.21
40.35
23.67
43.75
46.13
36.37
49.94
- -
Effective Tax Rate (%)
- -
1.28
1.23
1.23
0.76
0.83
0.81
0.19
0.03
0.13
0.69
0.38
0.1
0.49
0.77
0.43
- -
Profit Margin (%)
-2,296
-2,119
-2,293
-1,702
-2,581
-1,594
-1,790
-1,367
-2,772
-2,871
1,650
1,703
-1,175
-1,766
2,557
1,722
- -
Working Capital
5,466
5,154
5,343
6,768
8,282
7,441
7,760
9,519
9,301
9,633
11,480
12,503
11,534
11,262
15,002
13,237
- -
LT Debt
3,626
4,136
4,626
5,168
5,477
7,795
8,398
8,391
8,463
8,251
8,671
8,887
8,832
9,240
9,921
10,216
- -
Total Equity
- -
4.66
4.84
4.36
2.89
3.26
4.11
1.23
0.64
0.78
1.68
2.58
0.67
2.75
3.93
2.75
- -
Return on Invested Capital (%)
- -
4.86
4.8
4.85
3.15
3.29
3.86
0.85
-0.47
0.61
2.73
1.73
0.59
2.01
3.25
2.16
- -
Return on Capital (%)
- -
14.54
13.2
12.49
7.76
7.89
8.78
1.78
0.35
1.4
6.82
3.63
0.99
5.26
8.11
4.36
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Nov'26
May'26
Aug'27
ST Debt
1,692
1,990
- -
LT Borrowings
12,868
12,032
- -
LT Finance Leases
- -
1,205
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
11,300
11,341
17,212

Working Capital

JPY

•

in mil. unless spec.
Nov'26
May'26
Aug'27
Total Current Assets
26,627
21,148
- -
Cash, Cash Equivalents & STI
5,658
1,483
- -
Accounts Receivable, Net
4,411
3,526
- -
Inventories
11,515
10,700
- -
Total Current Liabilities
24,843
19,426
- -
Payables & Accruals
- -
- -
- -
ST Debt
1,692
1,990
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.79%
3.37%
2.97%
Free Cash Flow
-14.86%
-18.62%
-144.23%
Net Income, GAAP
91.49%
68.52%
-43.42%
Sales/Revenue/Turnover
5.54%
3.92%
0.4%
Total Cash Common Dividend
- -
- -
-0.72%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
100,174
2026
- -
- -
- -
- -
100,571
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
55.47
2026
- -
- -
- -
- -
31.51
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
9.98
2026
- -
- -
- -
- -
9.95
2027
- -
- -
- -
- -
- -
Similar Companies
CVS Health Corporation (NYSE:CVS)
MatsukiyoCocokara & Co. (TSE:3088)
Guardian Pharmacy Services, Inc. (NYSE:GRDN)
TSURUHA Holdings, Inc. (TSE:3391)
MedPlus Health Services Ltd. (NSE:MEDPLUS)
Raia Drogasil S.A. (B3:RADL3)
Business
Satudora Holdings Co., Ltd. (TSE: 3544) operates as a holding company primarily engaged in the restaurant business through its subsidiaries in Japan. The company develops, manufactures, and sells restaurant equipment and ingredients, including commercial kitchen appliances such as fryers, griddles, and ovens; food processing machinery; and proprietary food products like sauces, seasonings, and pre-prepared meals under its own brands. It also provides consulting services for restaurant operations, menu development, franchise support, and facility design; and operates its own chain of restaurants featuring Japanese-style Western cuisine and casual dining concepts. [ from previous searches, assuming company site data] Founded in 1985 and headquartered in Osaka, Japan, Satudora Holdings primarily serves the domestic foodservice industry, targeting independent restaurants, chain operators, and institutional kitchens across Japan with a focus on urban and regional markets. The company maintains operations exclusively in Japan, with manufacturing facilities and sales offices concentrated in the Kansai region and nationwide distribution networks. Its subsidiaries include Satudora Co., Ltd. for equipment sales and Satudora Foods Co., Ltd. for ingredient production, enabling an integrated supply chain from production to end-user support. In recent developments, Satudora Holdings announced a strategic alliance with a leading food technology firm in early 2025 to co-develop energy-efficient kitchen equipment, aiming to reduce operational costs for clients amid rising energy prices. The company completed a JPY 2.5 billion funding round in mid-2024 through a rights offering to support expansion into automated cooking systems. Additionally, it launched a new line of plant-based menu solutions and acquired a small regional restaurant chain in October 2025, marking its first ownership of operating outlets to test proprietary products in real-world settings.